Beacon Therapeutics Raises $170M in Series B Funding for Ophthalmic Gene Therapy

Beacon Therapeutics raises $170M in Series B Funding

Beacon Therapeutics (Linkedin) has secured $170 million in Series B funding, bringing their total funding to $290 million. They are focused on developing gene therapy treatments to save and restore the vision of patients with retinal diseases.

Funding Amount: $170 million

Industry: Biotechnology Research

Employee Count: 51-200

CEO: David Fellows (CEO Linkedin)

What Beacon Therapeutics needs to buy: Beacon Therapeutics is seeking partnerships with clinical research organizations, manufacturers, and regulatory experts in the field of gene therapy. Companies specializing in clinical research and development services, manufacturing and supply chain solutions, and regulatory and compliance expertise are ideal partners for Beacon Therapeutics to advance their mission of treating retinal diseases and restoring vision.